CN100402529C - 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 - Google Patents
用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 Download PDFInfo
- Publication number
- CN100402529C CN100402529C CNB038249901A CN03824990A CN100402529C CN 100402529 C CN100402529 C CN 100402529C CN B038249901 A CNB038249901 A CN B038249901A CN 03824990 A CN03824990 A CN 03824990A CN 100402529 C CN100402529 C CN 100402529C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- phenyl
- methyl
- group
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40913402P | 2002-09-09 | 2002-09-09 | |
| US60/409,134 | 2002-09-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1694883A CN1694883A (zh) | 2005-11-09 |
| CN100402529C true CN100402529C (zh) | 2008-07-16 |
Family
ID=31978719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038249901A Expired - Fee Related CN100402529C (zh) | 2002-09-09 | 2003-09-05 | 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7081463B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1601674B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4712384B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050043935A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100402529C (cg-RX-API-DMAC7.html) |
| AR (1) | AR041205A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003268512A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0306309A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2498275C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2003001814A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA009369B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05002622A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20051743L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ538307A (cg-RX-API-DMAC7.html) |
| PL (1) | PL377047A1 (cg-RX-API-DMAC7.html) |
| RS (1) | RS20050208A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI296627B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004022558A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200502836B (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003268512A1 (en) | 2002-09-09 | 2004-03-29 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| ZA200510329B (en) * | 2003-05-23 | 2007-04-25 | Zealand Pharma As | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
| US20060178390A1 (en) * | 2004-08-02 | 2006-08-10 | Alfonzo Jordan | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| ATE488519T1 (de) | 2005-09-28 | 2010-12-15 | Hoffmann La Roche | Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten |
| TW200819457A (en) * | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
| CN103202840B (zh) * | 2006-11-28 | 2015-02-11 | 詹森药业有限公司 | 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐 |
| CN101616669B (zh) * | 2006-11-28 | 2013-05-29 | 詹森药业有限公司 | 制备治疗酒精滥用、成瘾和依赖的药物 |
| EP2150552B1 (en) * | 2007-04-09 | 2013-01-02 | Janssen Pharmaceutica NV | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| US20100076003A1 (en) * | 2008-09-19 | 2010-03-25 | Kathleen Battista | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators |
| UA107943C2 (xx) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| US10118918B2 (en) | 2012-12-21 | 2018-11-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用 |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環(4.5)癸烷衍生物 |
| AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| MX381417B (es) | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| CN122562777A (zh) * | 2015-12-02 | 2026-08-14 | 阿斯特来亚治疗有限责任公司 | 哌啶基痛敏肽受体化合物 |
| JP6971999B2 (ja) | 2016-02-25 | 2021-11-24 | エースニューロン・ソシエテ・アノニム | ピペラジン誘導体の酸付加塩 |
| CN108884077A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| CA3110032A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S.A. | Succinate and fumarate acid addition salts of piperazine derivatives |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039029A1 (en) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006545A1 (en) * | 1998-07-27 | 2000-02-10 | Schering Corporation | High affinity ligands for nociceptin receptor orl-1 |
| EP0997464A1 (en) * | 1998-10-23 | 2000-05-03 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists |
| WO2001007050A1 (en) * | 1999-07-26 | 2001-02-01 | Schering Corporation | Nociceptin receptor orl-1 agonists for use in treating cough |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US677421A (en) * | 1900-10-19 | 1901-07-02 | Kate Hatch Mcrae | Cake-beater. |
| US3155699A (en) * | 1960-03-30 | 1964-11-03 | Mobay Chemical Corp | Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content |
| US3155670A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3161644A (en) * | 1962-06-22 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-benzyl-4-substituted piperidines |
| US3238216A (en) | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| US3839340A (en) * | 1968-09-27 | 1974-10-01 | Fmc Corp | Substituted 1,3,8-triazaspiro{8 4.5{9 decanes |
| US3629267A (en) * | 1968-10-28 | 1971-12-21 | Smith Kline French Lab | Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione |
| US3859340A (en) * | 1970-09-09 | 1975-01-07 | Squibb & Sons Inc | ' -methylfluorene-2-acetic acid |
| US4020072A (en) * | 1976-05-04 | 1977-04-26 | E. R. Squibb & Sons, Inc. | 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines |
| JPS54109983A (en) * | 1978-02-13 | 1979-08-29 | Sumitomo Chem Co Ltd | Novel spiroamine derivative and its preparation |
| US4329363A (en) * | 1978-09-08 | 1982-05-11 | Merck & Co., Inc. | Substituted mercapto acid amides and their use |
| US4526896A (en) * | 1978-12-26 | 1985-07-02 | Riker Laboratories, Inc. | Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof |
| US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
| JPS57212180A (en) * | 1981-06-19 | 1982-12-27 | Yoshitomi Pharmaceut Ind Ltd | Tetrahydrofuran(thiophene) compound |
| WO1988000190A1 (en) | 1986-06-25 | 1988-01-14 | Massachusetts Institute Of Technology | Optically active derivatives of glycidol |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| DE4135473A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | Triazaspirodecanon-methylchromane |
| WO1993012789A1 (en) | 1991-12-27 | 1993-07-08 | Beth Israel Hospital | Use of spiperone or spiperone derivatives as immunosuppressant agents |
| FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| JPH11500100A (ja) | 1993-09-09 | 1999-01-06 | サイオス ノバ インコーポレイテッド | 偽ペプチドおよび非ペプチドブラジキニンレセプターアンタゴニスト |
| US5739336A (en) | 1995-06-23 | 1998-04-14 | Syntex (U.S.A.) Inc. | 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| NZ326874A (en) | 1996-03-29 | 2000-01-28 | Pfizer | 6-phenylpyridyl-2-amine derivatives |
| CA2226058C (en) | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
| US6013652A (en) * | 1997-12-04 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin antagonists |
| SI0921125T1 (en) * | 1997-12-05 | 2002-04-30 | F. Hoffmann-La Roche Ag | 1,3,8-Triazaspiro(4,5)decan-4-on derivatives |
| DE69803653T2 (de) * | 1997-12-05 | 2002-08-29 | F. Hoffmann-La Roche Ag, Basel | 1,3,8-Triazaspiro[4,5]decan-4-on-derivate |
| JP2002515503A (ja) * | 1998-05-18 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン |
| US6277991B1 (en) * | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| ES2162503T3 (es) | 1998-06-12 | 2001-12-16 | Hoffmann La Roche | Derivados diaza-espiro(3,5)nonanos. |
| WO1999065494A1 (en) * | 1998-06-15 | 1999-12-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| JP2002530377A (ja) | 1998-11-20 | 2002-09-17 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | Nk−3およびnk−2受容体アンタゴニストとしてのキノリン−4−カルボキシアミド誘導体 |
| JP2000169476A (ja) | 1998-12-09 | 2000-06-20 | Banyu Pharmaceut Co Ltd | 4−オキソイミダゾリジン−5−スピロ−含窒素複素環式化合物 |
| AU1382901A (en) | 1999-11-17 | 2001-05-30 | Novo Nordisk A/S | Novel triazaspirodecanones with high affinity for opioid receptor subtypes |
| DE19956598A1 (de) | 1999-11-25 | 2001-06-13 | Bosch Gmbh Robert | Ventil zum Steuern von Flüssigkeiten |
| JP3989247B2 (ja) | 1999-12-06 | 2007-10-10 | ユーロ−セルティーク エス.エイ. | ノシセプチン受容体親和性を有するトリアゾスピロ化合物 |
| JP2005231995A (ja) * | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト/アンタゴニストとして有用なスピロ化合物 |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| WO2001096337A1 (en) | 2000-06-14 | 2001-12-20 | Banyu Pharmaceutical Co.,Ltd | 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds |
| MXPA03009239A (es) | 2001-04-10 | 2004-11-12 | Johnson & Johnson | Derivados de 1,3,8-triazapiro[4,5]decan-4-ona utiles para el tratamiento de trastornos mediados por el receptor orl-1. |
| CN1516584A (zh) | 2001-04-18 | 2004-07-28 | ŷ�����ǹɷ�����˾ | 螺吡唑化合物 |
| US20030078278A1 (en) * | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
| CA2454785C (en) * | 2001-07-23 | 2010-09-07 | Banyu Pharmaceutical Co., Ltd. | 4-oxoimidazolidine-2-spiropiperidine derivatives |
| US20040014955A1 (en) * | 2001-12-17 | 2004-01-22 | Carlos Zamudio | Identification of essential genes of cryptococcus neoformans and methods of use |
| EP1470126A1 (en) * | 2002-01-28 | 2004-10-27 | Pfizer Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| AU2003268512A1 (en) | 2002-09-09 | 2004-03-29 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| AU2004309419A1 (en) | 2003-12-23 | 2005-07-14 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| US7879834B2 (en) | 2004-08-19 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Spiroindoline modulators of muscarinic receptors |
| CA2581150A1 (en) | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
| EP2522669B1 (en) * | 2005-06-02 | 2016-12-28 | Janssen Pharmaceutica NV | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators |
| CN101616669B (zh) | 2006-11-28 | 2013-05-29 | 詹森药业有限公司 | 制备治疗酒精滥用、成瘾和依赖的药物 |
| EP2150552B1 (en) | 2007-04-09 | 2013-01-02 | Janssen Pharmaceutica NV | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| US20100076003A1 (en) | 2008-09-19 | 2010-03-25 | Kathleen Battista | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators |
-
2003
- 2003-09-05 AU AU2003268512A patent/AU2003268512A1/en not_active Abandoned
- 2003-09-05 PL PL377047A patent/PL377047A1/pl not_active Application Discontinuation
- 2003-09-05 NZ NZ538307A patent/NZ538307A/en unknown
- 2003-09-05 RS YUP-2005/0208A patent/RS20050208A/sr unknown
- 2003-09-05 JP JP2004534697A patent/JP4712384B2/ja not_active Expired - Fee Related
- 2003-09-05 BR BR0306309-7A patent/BR0306309A/pt not_active IP Right Cessation
- 2003-09-05 MX MXPA05002622A patent/MXPA05002622A/es active IP Right Grant
- 2003-09-05 WO PCT/US2003/027956 patent/WO2004022558A2/en not_active Ceased
- 2003-09-05 KR KR1020057003938A patent/KR20050043935A/ko not_active Ceased
- 2003-09-05 US US10/656,934 patent/US7081463B2/en not_active Expired - Lifetime
- 2003-09-05 EA EA200500331A patent/EA009369B1/ru not_active IP Right Cessation
- 2003-09-05 CN CNB038249901A patent/CN100402529C/zh not_active Expired - Fee Related
- 2003-09-05 CA CA2498275A patent/CA2498275C/en not_active Expired - Fee Related
- 2003-09-05 EP EP03749479A patent/EP1601674B1/en not_active Expired - Lifetime
- 2003-09-08 TW TW092124686A patent/TWI296627B/zh not_active IP Right Cessation
- 2003-09-08 AR ARP030103248A patent/AR041205A1/es unknown
- 2003-09-09 CL CL200301814A patent/CL2003001814A1/es unknown
-
2005
- 2005-04-07 ZA ZA200502836A patent/ZA200502836B/en unknown
- 2005-04-08 NO NO20051743A patent/NO20051743L/no not_active Application Discontinuation
- 2005-10-04 US US11/242,654 patent/US7582649B2/en not_active Expired - Lifetime
-
2008
- 2008-12-03 US US12/327,437 patent/US8778956B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006545A1 (en) * | 1998-07-27 | 2000-02-10 | Schering Corporation | High affinity ligands for nociceptin receptor orl-1 |
| EP0997464A1 (en) * | 1998-10-23 | 2000-05-03 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists |
| WO2001007050A1 (en) * | 1999-07-26 | 2001-02-01 | Schering Corporation | Nociceptin receptor orl-1 agonists for use in treating cough |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050043935A (ko) | 2005-05-11 |
| EP1601674B1 (en) | 2012-08-08 |
| CL2003001814A1 (es) | 2005-02-11 |
| CA2498275A1 (en) | 2004-03-18 |
| RS20050208A (sr) | 2007-08-03 |
| US20090124614A1 (en) | 2009-05-14 |
| EA200500331A1 (ru) | 2005-08-25 |
| US7081463B2 (en) | 2006-07-25 |
| JP4712384B2 (ja) | 2011-06-29 |
| TWI296627B (en) | 2008-05-11 |
| WO2004022558A3 (en) | 2004-05-21 |
| AU2003268512A1 (en) | 2004-03-29 |
| NZ538307A (en) | 2008-04-30 |
| EP1601674A2 (en) | 2005-12-07 |
| US8778956B2 (en) | 2014-07-15 |
| MXPA05002622A (es) | 2005-09-08 |
| CN1694883A (zh) | 2005-11-09 |
| BR0306309A (pt) | 2004-10-19 |
| AR041205A1 (es) | 2005-05-11 |
| US20060030577A1 (en) | 2006-02-09 |
| WO2004022558A2 (en) | 2004-03-18 |
| PL377047A1 (pl) | 2006-01-23 |
| JP2006500393A (ja) | 2006-01-05 |
| US7582649B2 (en) | 2009-09-01 |
| EA009369B1 (ru) | 2007-12-28 |
| TW200418857A (en) | 2004-10-01 |
| CA2498275C (en) | 2011-07-12 |
| US20040142955A1 (en) | 2004-07-22 |
| ZA200502836B (en) | 2006-06-28 |
| NO20051743L (no) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1601674B1 (en) | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | |
| DE60021630T2 (de) | Tricyclische kondensierte heterocyclische Verbindungen als CRF Antagonisten | |
| TW202043212A (zh) | Shp2抑制劑及其應用 | |
| DE69531476T2 (de) | Serotonergische Modulatoren | |
| CN109843888A (zh) | 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物 | |
| CN101679430B (zh) | 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物 | |
| CN106164076B (zh) | 作为ros1抑制剂的化合物 | |
| CN102939283A (zh) | 可用作己酮糖激酶抑制剂的吲唑化合物 | |
| TW201111356A (en) | Nitrogen-containing compound and pharmaceutical composition | |
| CA3003559C (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors | |
| DE60206952T2 (de) | Imidazopyridinverbindungen als 5-ht4-rezeptormodulatoren | |
| CA2468705A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
| JPS60215683A (ja) | 新規縮合ジアゼピノン | |
| DE69829317T2 (de) | Tetrahydrobenzindol-derivate | |
| CN119384420A (zh) | 新型par-2抑制剂 | |
| CN101227903A (zh) | 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物 | |
| CN101321726A (zh) | 新型稠合吡咯衍生物 | |
| Modica et al. | Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands | |
| HU228314B1 (hu) | Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| AU594489B2 (en) | Substituted pyrido(2,3-b)(1,4) Benzodiazepin-6-ones | |
| CA1321996C (en) | Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds | |
| HUT61301A (en) | Process for producing condensed diazepinone derivatives and pharmaceutical compositions comprising same as active ingredient | |
| DE602004005893T2 (de) | Trizyklische 1-((3-indol-3-yl)-carbonyl)-piperazin-derivate als cannabinoid-cb1-rezeptoragonisten | |
| KR20200118008A (ko) | 테트라하이드로피롤계 화합물, 그의 제조방법, 약학조성물 및 용도 | |
| EP3530651A1 (en) | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080716 Termination date: 20170905 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |